Norges Bank Takes $7.76 Million Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Norges Bank purchased a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 607,800 shares of the biopharmaceutical company's stock, valued at approximately $7,762,000. Norges Bank owned approximately 0.46% of Dynavax Technologies at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in DVAX. Smartleaf Asset Management LLC increased its holdings in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Dynavax Technologies in the fourth quarter valued at approximately $71,000. Nisa Investment Advisors LLC boosted its position in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 1,076 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth approximately $89,000. Hedge funds and other institutional investors own 96.96% of the company's stock.

Dynavax Technologies Price Performance

NASDAQ:DVAX traded up $0.14 during trading hours on Monday, reaching $11.39. 89,055 shares of the company traded hands, compared to its average volume of 2,317,703. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $14.63. The stock has a market cap of $1.41 billion, a P/E ratio of 63.26 and a beta of 1.26. The firm's 50-day moving average is $13.20 and its 200-day moving average is $12.59. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Equities research analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVAX has been the topic of several research analyst reports. The Goldman Sachs Group lowered shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price objective for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. HC Wainwright reissued a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, StockNews.com upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.